(NASDAQ: SRPT) Sarepta Therapeutics's forecast annual revenue growth rate of -16.08% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 97.96%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.83%.
Sarepta Therapeutics's revenue in 2025 is $2,413,715,000.On average, 29 Wall Street analysts forecast SRPT's revenue for 2025 to be $226,654,685,481, with the lowest SRPT revenue forecast at $207,269,055,886, and the highest SRPT revenue forecast at $238,181,276,051. On average, 29 Wall Street analysts forecast SRPT's revenue for 2026 to be $168,497,796,696, with the lowest SRPT revenue forecast at $134,127,599,360, and the highest SRPT revenue forecast at $245,935,527,889.
In 2027, SRPT is forecast to generate $159,381,311,427 in revenue, with the lowest revenue forecast at $109,816,971,976 and the highest revenue forecast at $206,221,184,016.